Deals and M&A

Rapt licenses FLX-475 to Hanmi in deal worth up to $118M

December 10, 2019

HONG KONG – Rapt Therapeutics Inc., of San Francisco, and Seoul, South Korea-based Hanmi Pharmaceutical Co. Ltd. entered a license agreement for Rapt’s FLX-475 in Asia. FLX-475 is an oral, small-molecule CCR4 antagonist for cancer treatment.

Luye Pharma bids to acquires Boan in $205M deal to compete in biologics

December 10, 2019

By Elise Mak

No Comments

BEIJING – Luye Pharma Group Ltd., of Yantai, Shandong Province of China, has proposed to acquire Shandong Boan Biological Technology Co. Ltd. for up to $205.8 million to expand and diversify its pipeline portfolio into biologics. The payment is to be in three parts: an initial amount of $102.9 million, followed by payments linked to China marketing approval for two of Boan’s candidates of $51.45 million each.

Alteogen licenses ALT-B4 to a top 10 global pharma in potential $1B+ deal

December 3, 2019

By Jihyun Kim

No Comments

HONG KONG – South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human hyaluronidase enzyme, ALT-B4, in exchange for an up-front payment of $13 million. It is also eligible to receive additional payments of up to $1.37 billion tied to the achievement of development, regulatory approval and sales milestones. While the undisclosed big pharma will secure the global rights to develop and commercialize multiple products in combination with the Hybrozyme technology, Alteogen will be responsible for the clinical and commercial supply of ALT-B4 materials.

GI Innovation licenses GI-101 to Simcere at maximum $796 million

December 3, 2019

By Jihyun Kim

No Comments

HONG KONG – Seoul, South Korea-based GI Innovation Inc. has licensed to Nanjing, Jiangsu-based Simcere Pharmaceutical Co. Ltd. rights to its immunotherapy drug candidate, G1-101, a bispecific CD80/interleukin2 (IL-2) variant fusion protein.

Samsung Bioepis inks $100M deal with Biogen for two upcoming biosimilars and more

November 10, 2019

By David Ho

No Comments

HONG KONG – South Korea's Samsung Bioepis Co. Ltd. will get $100 million in up-front payments in a commercialization deal for two of its biosimilar candidates with U.S. company Biogen Inc. Under the deal, Samsung Bioepis will also be eligible for up to $270 million in milestone and option payments, as well as a share of sales revenue.

Beigene, Amgen ink $2.7B China deal

November 6, 2019

By Lee Landenberger and Elise Mak

No Comments

When the time was right to make a powerful Western biotech welcome in China, Beigene Ltd. was ready when Amgen Inc. came calling. Its massive $2.7 billion cash equity investment in Beigene buys Amgen an oncology footprint in China.

Pascal, Y-biologics to collaborate in bispecific antibodies for leukemia

November 6, 2019

By Jihyun Kim

No Comments

HONG KONG – Canadian company Pascal Biosciences Inc., headquartered in Vancouver, and South Korean biotech Y-biologics Inc., based in Daejeon, have signed a research collaboration agreement for the discovery and development of bispecific antibodies for the treatment of leukemia.

Azoth and Wellmarker Bio to collaborate in AI-based cancer drug development

November 6, 2019

By Jihyun Kim

No Comments

South Korean AI-based biotech Azoth Bio Inc., of Seongnam, Gyeonggi-do, and biopharmaceutical venture Wellmarker Bio Co. Ltd., based in Seoul, have signed a memorandum of understanding for cancer drug R&D and commercialization.

Qurient inks joint venture with Max Planck Society and Lead Discovery Center in Germany

October 30, 2019

By Jihyun Kim

No Comments

HONG KONG – South Korean biotech company Qurient Co. Ltd. has inked a joint venture (JV) foundation deal involving Germany's Max Planck Society (MPG), of Munich, and Lead Discovery Center GmbH (LDC) in Dortmund, as well as the 1988 Nobel laureate and biochemist Robert Huber.

GC Pharma, Vaxess partner on global commercialization of flu vaccine patch

October 30, 2019

By Jihyun Kim

No Comments

HONG KONG – One of South Korea's biggest pharmaceutical companies by market capitalization, GC Pharma Corp., based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech Vaxess Technologies Inc., have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology.

Deals and M&A, BioWorld Asia
RSS

Rapt licenses FLX-475 to Hanmi in deal worth up to $118M

Luye Pharma bids to acquires Boan in $205M deal to compete in biologics

Alteogen licenses ALT-B4 to a top 10 global pharma in potential $1B+ deal

GI Innovation licenses GI-101 to Simcere at maximum $796 million

Samsung Bioepis inks $100M deal with Biogen for two upcoming biosimilars and more

Beigene, Amgen ink $2.7B China deal

Pascal, Y-biologics to collaborate in bispecific antibodies for leukemia

Azoth and Wellmarker Bio to collaborate in AI-based cancer drug development

Qurient inks joint venture with Max Planck Society and Lead Discovery Center in Germany

GC Pharma, Vaxess partner on global commercialization of flu vaccine patch

Popular Stories

Bioworld MedTech’s Oncology Extra

FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

Biopharma companies continue their strong momentum in November

BioWorld Premium

Deals and M&A, BioWorld Asia RSS

Popular Stories

BioWorld Premium

Deals and M&A, BioWorld Asia
RSS